secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262795
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations
--------------------------------------------------------------------------------

- Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.
- Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.
- Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.
- Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.
- Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/0001193125-25-262795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer